MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$11.25 +0.69%

+$0.13 today

Market cap
$957.45M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.17M

Average 0.99M

Returns on capital

MoonLake Immunotherapeutics management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-74.7%

avg 41.6%

ROIC

-64.4%

avg -281.7%

ROA

-53.6%

avg -117.4%

Analysis

ROA is currently the strongest return metric at -53.6% versus its period average of -117.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Kristian Reich

Co-Founder & Chief Scientific OfficerUSD 795.47K602.71M3.68%

Jorge Santos da Silva

Co-Founder, Interim Chair of the Board & CEOUSD 787.31K492.77M3.77%

Matthias Bodenstedt

Chief Financial OfficerUSD 626.53K381.12M1.52%

Luciana Marques

Associate Vice-President of HR, People and Culture————

Nicolas Mosimann

General Counsel————

Tino Anthamatten

Vice President of Marketing, Market Access & Pricing————

Oliver Daltrop

Chief Technical Officer————

Carla Bretes

Director of Investor Relations & External Communications————

Nuala Brennan

Chief Clinical Development Officer————

Joana Cortez

Associate Vice-President of Legal & Compliance————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 27, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

27

$83.03M

Net Transaction Value

−$83.03M

Net selling

Most Active

Reich Kristian

10 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 27, 26

Reich Kristian

Indirect

Sell$22K
Jul 22, 26

Reich Kristian

Indirect

Sell$49K
Jul 21, 26

Reich Kristian

Indirect

Sell$1M
Jul 20, 26

Reich Kristian

Indirect

Sell$877.9K
Jul 15, 26

Reich Kristian

Indirect

Sell$322.3K
Jul 10, 26

Santos da Silva Jorge

Direct

Sell$1.4M
Jul 9, 26

Santos da Silva Jorge

Direct

Sell$679.1K
Jul 1, 26

Santos da Silva Jorge

Direct

Sell$956.9K
Jun 22, 26

Bodenstedt Matthias

Direct

Sell$862.2K
Jun 18, 26

Bodenstedt Matthias

Direct

Sell$54.8K

1–10 of 27

Summary

Insiders reported 0 buys worth $0.00 and 27 sells worth $83.03M over the last 12 months. That adds up to net selling of $83.03M. Reich Kristian was the most active insider with 10 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does MoonLake Immunotherapeutics compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MLTX's management, answered from reported figures.

Who manages MLTX?

MoonLake Immunotherapeutics (MLTX) lists 10 active executives. The top listed executive is Luciana Marques, Associate Vice-President of HR, People and Culture.

Are MLTX insiders buying or selling?

Recent insider activity shows net selling of $144.39M.